Commercial Operations

Research and Development

Our Research and Development (R&D) efforts are dedicated to creating new and innovative pharmaceuticals for the treatment of psychiatric and neurological disorders. Through investment and perseverance, we strive to create the very best treatments for patients.  

We are the only fully-integrated pharmaceutical company in the world, solely devoted to the treatment of psychiatric and neurological disorders. We dedicate our entire R&D efforts to develop innovative drugs for treatment of a number of psychiatric and neurological disorders. Our R&D projects focus on: Alzheimer’s disease, Depression, Parkinson’s disease, and Schizophrenia.  

Title Location Country
Reset
Sr. Medical Advisor, Bexicaserin and DEE, Global Medical Affairs
Sr. Medical Advisor, Bexicaserin and DEE, Global Medical Affairs Copenhagen, Danish Capital Region, DK 29 Sept 2025 0.00 km
Copenhagen, Danish Capital Region, DK Denmark
Sr. Director, Head of Amlenetug and MSA, Global Medical Affairs
Sr. Director, Head of Amlenetug and MSA, Global Medical Affairs Copenhagen, Danish Capital Region, DK 29 Sept 2025 0.00 km
Copenhagen, Danish Capital Region, DK Denmark
Global Scientific Communications Lead - Amlenetug and MSA
Global Scientific Communications Lead - Amlenetug and MSA Copenhagen, Danish Capital Region, DK 29 Sept 2025 0.00 km
Copenhagen, Danish Capital Region, DK Denmark
Sr. Director, Head of Bexicaserin and DEE, Global Medical Affairs
Sr. Director, Head of Bexicaserin and DEE, Global Medical Affairs Copenhagen, Danish Capital Region, DK 29 Sept 2025 0.00 km
Copenhagen, Danish Capital Region, DK Denmark